ANAB Live-Signale | Maximieren Sie Profite mit Getagraph.com

KAUFEN 109733 min ago

@ $22.40

Ausgestellt: 13 Feb 2024 @ 15:30

Rendite: -3.88%

Vorheriges Signal: Feb 12 - 15:36

Vorheriges Signal: Verkaufen

Rendite: -3.80 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 21:22):

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications...

Stats
Tagesvolumen	492 830
Durchschnittsvolumen	333 532
Marktkapitalisierung	588.17M
EPS	$0 ( 2024-03-13 )
Nächstes Ertragsdatum	( $-1.540 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.54
ATR14	$0.0890 (0.41%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-22	Faga Daniel	Sell	145 940	Common Stock
2024-03-25	Faga Daniel	Sell	3 000	Common Stock
2024-03-26	Faga Daniel	Sell	347 441	Common Stock
2024-02-16	Loumeau Eric J	Sell	5 000	Employee Stock Option (right to buy)
2024-02-16	Loumeau Eric J	Buy	5 000	Common Stock

INSIDER POWER
37.37
Last 98 transactions
Buy: 3 215 504 \| Sell: 1 263 529

Volumen Korrelation

Lang: -0.29 (neutral)

Kurz: 0.06 (neutral)

Signal:(31.516) Neutral

AnaptysBio Inc Korrelation

10 Am meisten positiv korreliert
CDXS	0.959
TRIP	0.957
ZD	0.956
SRTS	0.954
CSGS	0.953
ETSY	0.95
LGHL	0.944
HNNA	0.941
NMTR	0.94
VERI	0.94

10 Am meisten negativ korreliert
MSDA	-0.938
DHAC	-0.929
MCAA	-0.928
MYRG	-0.92
BRIV	-0.918
RELY	-0.917
SKYA	-0.917
BRIVU	-0.916
FICV	-0.914
ADAL	-0.914

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

AnaptysBio Inc Korrelation - Währung/Rohstoff

-0.35
( neutral )

-0.50
( weak negative )

0.00
( neutral )

-0.09
( neutral )

-0.72
( moderate negative )

-0.36
( neutral )

AnaptysBio Inc Finanzdaten

Annual	2023
Umsatz:	$17.16M
Bruttogewinn:	$14.78M (86.15 %)
EPS:	$-6.08

FY	2023
Umsatz:	$17.16M
Bruttogewinn:	$14.78M (86.15 %)
EPS:	$-6.08

FY	2022
Umsatz:	$10.29M
Bruttogewinn:	$7.95M (77.30 %)
EPS:	$-4.57

FY	2021
Umsatz:	$63.18M
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-2.11

Financial Reports:

No articles found.

AnaptysBio Inc

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.